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by themeans of subjective constipation symptoms. Remarkably, CTTs in
clozapine were four times longer than for other antipsychotics or
population norms and 4 of 5 clozapine-treated patients showed clearClozapine is still the most effective antipsychotic drug in the man- hypomotility (Every-Palmer et al., 2016). Therefore, the work of
agement of treatment-resistant schizophrenia and alternative strategies
are currently not foreseeable. Clinicians are aware of the typical and fre-
quent clozapine side-effects such as hypotension, sedation, tachycardia
and sialorrhea aswell as the rare but nevertheless life-threatening com-
plications like agranulocytosis or myocarditis. However, clozapine-
induced constipation with the consecutive risk for ileus still receives
little attention, which is a matter of concern: (1) constipation linked
to antipsychotic treatment is generally underestimated (De Hert et al.,
2011a) and (2) clozapine seems to be speciﬁcally associated with
high-grade constipation, intestinal obstruction and paralytic ileus
(De Fazio et al., 2015; Palmer et al., 2008; DeHert et al., 2011b). Interna-
tional guidelines address antipsychotic-induced constipation (Hasan
et al., 2012) and provide evidence-based pharmacological and non-
pharmacological treatment recommendations based on a sparse
database (Hasan et al., 2013). To ﬁll the clinician's knowledge gap,
new evidence regarding antipsychotic-induced constipation and the
relationship to certain compounds is needed.
Every-Palmer et al. (2016) provide a novel and important study to
shed more light on this relationship. They used for the very ﬁrst time
a standardized radiopaquemarker method (multiple radiopaquemark-
er (ROM) bolus technique) to measure colonic transit times (CTTs) of
patients receiving antipsychotics aswell as comparing the effects of clo-
zapine and non-clozapine antipsychotic agents on CCT. This approach is
new for clinical psychiatry and allows for a reliable and objective mea-
sure of CCT with limited burden for the patients. Their work is of partic-
ular signiﬁcance, as it (1) reveals for the ﬁrst time increased CTTs in
nearly all patients receiving clozapine (but surprisingly not in non-
clozapine treated patients), (2) that this is associatedwith the clozapinee-treated patients have marked
fe-threatening gastrointestinal
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e.
. This is an open access article underEvery-Palmer et al. (2016) will force clinical psychiatrists in future to
think about new strategies to assess clozapine-induced gastrointestinal
hypomotility in terms of using objective measures rather than counting
solely on the patients' subjective complaints. The disparity between
subjective symptoms and objective measures of prolonged CTTs is
discussed in the paper of Every-Palmer et al. (2016) as a multifactorial
effect of reduced pain sensitivity and the difﬁculty to communicate dis-
comfort of schizophrenia patients, as well as the sedative component of
clozapine in general. Other publicationsdiscuss the presence of negative
symptoms, the social isolation of patients, the unhealthy lifestyle with
low physical activity and limited ﬂuid intake, but also physicians lacking
awareness, as reasons why somatic comorbidities, like constipation, are
not detected in schizophrenia patients (DeHert et al., 2011b). This study
highlights the fact that gastrointestinal hypomotility should be expect-
ed in a magnitude of patients treated with clozapine and that objective
measures might be needed to detect this side-effect before severe com-
plications appear. Surprisingly, patients receiving other, so called non-
clozapine antipsychotics, showed in the work of Every-Palmer et al.
(2016) transit times within the normal range contrasting clinical expe-
rience and previous data indicating an increased risk for constipation
following the treatment with various antipsychotics (De Hert et al.,
2011b). The reason for this discrepancy remains unclear and further re-
search is needed to disentangle the complex interplay between CTTs
and constipation in patients treated with non-clozapine antipsychotics.
More research is also necessary to evaluate the predictive value of in-
creased CTT and severe treatment complications in schizophrenia
patients.
For clinical psychiatry, this new data conﬁrms the need for an active
and systematic screening and monitoring of constipations symptoms
(De Hert et al., 2011b). This includes also the need to use objectivemea-
sures (including radiology and ultrasound) as well as the use of diaries
to access defecation frequency and the importance of physical examina-
tions to detect abdominal pathology in patients receiving antipsy-
chotics. Saying this, one should bear in mind that antipsychotics
are not exclusively used in schizophrenia patients (although clozapine
is mainly conﬁned to schizophrenia), but also in nearly all otherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and gastrointestinal hypomotility is of general importance in psychiatry.
Interestingly, the authors also reported a positive correlation between
serum clozapine levels and longer transit times. Treatment guidelines
recommend high clozapine-levels ≥ 350 ng/ml (Hasan et al., 2012;
Buchanan et al., 2010) in treatment-resistant schizophrenia and these
presented ﬁndings demonstrate that we need to pay special attention
to gastrointestinal complications in those patients who are at risk for
an unfavorable clinical course. Moreover, the issue of a potential indica-
tion extension of clozapine as a last resort antipsychotic in terms of its
earlier application is under discussion (Remington et al., 2013) and a re-
cently published retrospective cohort study underlined the superior ef-
fectiveness of clozapine with regard to the time to hospitalization and
the risk for treatment discontinuation (Stroup et al., 2016). Therefore,
it might be reasonably assumed that clozapine will remain one of
the most important antipsychotics and prescription rates may even
increase.
Considering thework of Every-Palmer et al. (2016), we need to focus
our attention on gastrointestinal hypomotility and consider speciﬁc
interventions. While the authors recommend prophylactic laxative
treatment based on evidence from the use of long-term opioids,
schizophrenia treatment guidelines pronounce the efﬁcacy of lifestyle
modulations and nutrition advice (Hasan et al., 2013). However, if the
underlying problem is mainly gut dysmotility as indicated by the
discussed paper (Every-Palmer et al., 2016), the aforementioned inter-
vention could be inadequate to treat this signiﬁcant treatment side-
effect. Further research is needed to evaluate evidence-based treatment
recommendation and prevention strategies for antipsychotic-induced
constipation. Although the paper by Every-Palmer et al. (2016) demon-
strates a discrepancy between objective measures of gastrointestinal
hypomotility and subjective symptom presentation, we should notforget, independent of such high-quality ﬁndings, that barriers to so-
matic monitoring and treatment are one of the major causes of excess
mortality in schizophrenia patients (De Hert et al., 2011b).References
Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., et al., Jan 2010. The 2009 schizophrenia PORT
psychopharmacological treatment recommendations and summary statements.
Schizophr. Bull. 36 (1), 71–93.
De Fazio, P., Gaetano, R., Caroleo, M., et al., 2015. Rare and very rare adverse effects of
clozapine. Neuropsychiatr. Dis. Treat. 11, 1995–2003.
De Hert, M., Correll, C.U., Bobes, J., et al., Feb 2011b. Physical illness in patients with severe
mental disorders. I. Prevalence, impact of medications and disparities in health care.
World Psychiatry Off. J. World Psychiatr. Assoc. 10 (1), 52–77.
De Hert, M., Hudyana, H., Dockx, L., et al., Jan 2011a. Second-generation antipsychotics
and constipation: a review of the literature. Eur. Psychiatry J. Assoc. Eur. Psychiatr.
26 (1), 34–44.
Every-Palmer, S., Nowitz, M., Stanley, J., et al., 2016. Clozapine-treated patients have
marked gastrointestinal hypomotility, the probable basis of life-threatening gastroin-
testinal complications: a cross sectional study. EBioMedicine 5, 125–134.
Hasan, A., Falkai, P., Wobrock, T., et al., Jul 2012.World Federation of Societies of Biological
Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: up-
date 2012 on the acute treatment of schizophrenia and themanagement of treatment
resistance. World J. Biol. Psychiatry 13 (5), 318–378.
Hasan, A., Falkai, P., Wobrock, T., et al., Feb 2013. World Federation of Societies of Biolog-
ical Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2:
update 2012 on the long-term treatment of schizophrenia and management of
antipsychotic-induced side effects. World J. Biol Psychiatry 14 (1), 2–44.
Palmer, S.E., McLean, R.M., Ellis, P.M., Harrison-Woolrych, M., May 2008. Life-threatening
clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin
Psychiatry 69 (5), 759–768.
Remington, G., Agid, O., Foussias, G., Hahn, M., Rao, N., Sinyor, M., Feb 2013. Clozapine's
role in the treatment of ﬁrst-episode schizophrenia. Am. J. Psychiatry 170 (2),
146–151.
Stroup, T.S., Gerhard, T., Crystal, S., Huang, C., Olfson, M., Feb. 1, 2016. Comparative
effectiveness of clozapine and standard antipsychotic treatment in adults with
schizophrenia. Am. J. Psychiatry 173 (2), 166–173.
